Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Sanofi SA — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $35.44, while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA pays a 5.61% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| NVDL | SNY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $52.34 |
52-Week Low | $21.76 | $41.33 |
Market Cap | — | $104.06B |
Enterprise Value | — | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% amid recent volatility. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF recently underwent two 1:3 stock splits in late June 2026, reflecting NVIDIA's continued market leadership in AI semiconductors.
The outlook remains positive given NVIDIA's dominant AI position and earnings beats, though leveraged ETF structure introduces volatility decay risks. Key opportunities include exposure to NVIDIA's growth trajectory, while risks center on market sentiment shifts and the ETF's daily reset mechanism affecting long-term returns.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
